Efficacy of indacaterol is maintained in patients with moderate or less and severe or worse COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Salmeterol/fluticasone therapy improves FEV1 in mild and moderate more than in severe COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004
Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Improvement of dyspnoea following of six months treatment with tiotropium but not with salmeterol in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 26s Year: 2001
Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials Source: Eur Respir J 2006; 28: Suppl. 50, 175s Year: 2006
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Two-year safety of targeted lung denervation in patients with moderate to severe COPD Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more Year: 2015
Withdrawal of inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: who is suitable for a trial of withdrawal? Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006
Premature discontinuation of patients: a potential bias in COPD clinical trials Source: Eur Respir J 2007; 30: 898-906 Year: 2007